ArticleCancer medicine2024

Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.

Liang Qiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.